Real life submission to the main board of the Hong Kong Stock Exchange, with China International Capital Corporation as its exclusive sponsor.

The prospectus shows that RealBio is a biotechnology company driven by innovative research and development, focusing on the development, manufacturing, and commercialization of innovative drugs for the treatment of viral infections, tumors, and cardiovascular and cerebrovascular diseases. Our mission is to improve human health through true innovation, especially in the fields of antiviral and anti-tumor treatments, exploring and addressing the issue of drug resistance in existing treatment options. The company aims to seek updated and better treatment options to address unmet clinical needs.

With rich experience in drug development, RealBio has established a comprehensive research and development platform, including a highly selective new nucleoside broad-spectrum anti-tumor drug development platform, TOPO1 inhibitor and XDC drug development platform, drug target discovery and validation platform, and innovative drug design and optimization platform. These platforms cover the entire drug development process, from early target screening to preclinical research, to clinical trials and subsequent optimization, providing strong technical support and systematic guarantees for accelerating the discovery and development of innovative drugs.

In the field of virus infection treatment, Azvudine, the core product of Realbio, as a Class 1.1 original new drug, was conditionally approved by the National Medical Products Administration for the treatment of HIV infection in July 2021 and for the treatment of COVID-19 in July 2022, becoming the first oral antiviral drug developed by a Chinese company to be approved by the National Medical Products Administration for the treatment of COVID-19. It has demonstrated outstanding effectiveness in the field of virus infection treatment: not only can it inhibit virus replication, but it can also achieve the effect of treating both symptoms and root causes by enhancing immune function. Currently, it has sold over 10 million bottles, and its safety and effectiveness have been confirmed in real-world data and 70 independent third-party published papers. Azvudine, with its unique dual target mechanism of action, has pioneered a treatment regimen for nucleoside reverse transcriptase and Vif helper protein dual target inhibition worldwide.

In addition, in phase II clinical trials, Azvudine achieved comparable clinical efficacy compared to Lamivudine (another popular NRTI) at a dose level of only 1%. Due to its significant therapeutic effect on viral infections and long-lasting mechanism, the company's Azvudine/CL-197 compound tablets have the potential to become the world's first fully oral long-acting, once weekly HIV treatment drug. The company also relies on its independent research and development capabilities to continuously expand the application of Azvudine in new indications and combination therapies in the field of cancer treatment.

In the field of cancer treatment, Azvudine, a core product discovered by real life, has broad-spectrum anti-tumor activity and is the only nucleoside based anti-tumor drug with dual mechanisms and high selectivity in the past 30 years. It exerts a dual anti-tumor effect by inhibiting DNA synthesis in tumor cells and regulating immune system function. The company is continuously expanding its core product Azvudine for new indications and combination therapies, including Azvudine/anti-PD-1 combination therapy for the treatment of liver cancer and colorectal cancer. Animal experimental data shows that 100% tumor elimination has been achieved; Azvudine/Doxetinib combination therapy is used to treat non-small cell lung cancer, and animal models show a tumor inhibition rate of 92.82%; As well as Azvudine monotherapy and Azvudine/CTX combination therapy for the treatment of hematological tumors, animal experimental data shows that monotherapy has a significant inhibitory effect on hematological tumors and achieves 100% tumor elimination in combination therapy.

In addition, the TOPO1 inhibitor platform developed by the ZS-1003 real life project adopts a groundbreaking non camptothecin core structure, demonstrating broad-spectrum anti-tumor activity. This drug has unique advantages in overcoming common anti-tumor drug resistance. Preclinical studies have shown that its inhibitory effect on irinotecan resistant tumor cells is 400 times that of irinotecan; And it is expected to be widely used as a new toxin in various XDC (such as ADC, PDC, SMDC, etc.) coupled drug projects, providing an effective solution to address drug resistance in multiple tumors.